Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

Next Previous
Trial Profile

Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil (Primary)
  • Indications Lewy body disease
  • Focus Therapeutic Use

Most Recent Events

  • 14 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
  • 16 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
  • 16 Oct 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top